Skip to main content
  • Entresto Signals Expansion Into 'Gray Zone' of HFpEF

    PARAGON-HF may have missed overall, but HF docs see reason for hope

    PARIS -- Sacubitril/valsartan (Entresto) struck out on heart failure with preserved ejection fraction (HFpEF) in the PARAGON-HF trial but signaled benefit in the lower range of EF.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details